{"id":1456,"date":"2022-12-15T09:30:00","date_gmt":"2022-12-15T09:30:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-receives-additional-orders-of-cadscorsystem-in-louisiana-usa\/"},"modified":"2024-08-06T12:25:00","modified_gmt":"2024-08-06T12:25:00","slug":"acarix-receives-additional-orders-of-cadscorsystem-in-louisiana-usa","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-receives-additional-orders-of-cadscorsystem-in-louisiana-usa\/","title":{"rendered":"Acarix receives additional orders of CADScor\u00aeSystem in Louisiana, USA"},"content":{"rendered":"
\n

Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today that the company has received additional orders for the CADScor\u00aeSystem in Louisiana. The orders are a result of a previously announced collaboration with Bio-Rhythms Inc, targeting an area with the highest prevalence of heart disease in the United States.<\/strong><\/p>\n<\/div>\n

\n

Louisiana is in the top-5 of US states based on heart disease death rates, due to a high frequency of obesity, diabetes, and kidney disease, all of which are risk factors for heart disease. The number of patients and the need for rapid assessment and exclusion of heart disease is therefore high.<\/p>\n

\u201cThere are many options for diagnostic testing to evaluate the presence of significant coronary artery disease, but many of them require multiple patient visits and can be invasive in nature,\u201d stated Dr. Ghiath Mikdadi, MD of the Heart Clinic of Hammond, a leading cardiac care clinic. \u201cWe are pleased to add the CADScor\u00aeSystems into our workflow as a first-line diagnostic aid to rule out patients before putting them through unnecessary advanced diagnostic testing.\u201d<\/p>\n

The Acarix CADScor\u00aeSystem is an acoustic and AI-based solution to rapidly and non-invasively evaluate patients with chest pains in 10 minutes. Its CPT-III code became effective in July 2022, and clinics are now receiving reimbursement payments from US insurance companies.<\/p>\n

"Our focus on the US market and the approximately 18 million patients who annually seek care for chest pain continues to generate results. With our own reimbursement code active since July 2022, healthcare providers can now quickly evaluate patients with chest pain and secure successful reimbursement compensation. This leads to a positive impact on patient care, patient volumes and health care financials", comments Helen Ljungdahl Round, President and CEO of Acarix.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46\u00a0730 770283, email helen.round@acarix.com<\/a>\u00a0
Christian Lindholm, CFO, phone +46\u00a0705 118333, email christian.lindholm@acarix.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor\u00aeSystem is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor\u00aeSystem uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se<\/a>) is Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a>.\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix receives additional orders of CADScor\u00aeSystem in Louisiana, USA<\/a><\/p>\n<\/div>\n